Status:
COMPLETED
ICATA Asthma Mechanistic Study
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)
Conditions:
Asthma
Eligibility:
All Genders
6-20 years
Brief Summary
The purposes of this study are to determine the effects of omalizumab on cells involved in the allergic response, to evaluate predictors of response to omalizumab, and to determine whether response to...
Detailed Description
Immunoglobulin E (IgE) is important in the development of allergic responses and may determine asthma severity. Omalizumab is a man-made monoclonal antibody that directly blocks the cause of allergic ...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Currently enrolled in ICATA (ICAC-08, NCT00377572) Clinical Study
- Positive skin test to German cockroach required for participation in the basophil and T-cell studies and associated procedures
- Cockroach insensitive participants will serve as control groups
Exclusion
Key Trial Info
Start Date :
October 1 2006
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2009
Estimated Enrollment :
224 Patients enrolled
Trial Details
Trial ID
NCT00377390
Start Date
October 1 2006
End Date
December 1 2009
Last Update
February 7 2013
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
Children's Memorial Hospital
Chicago, Illinois, United States, 60614
2
Mount Sinai School of Medicine
New York, New York, United States, 10029
3
Rainbow Babies and Children's Hospital
Cleveland, Ohio, United States, 44106
4
University of Texas Southwestern Medical Center
Dallas, Texas, United States, 75390